PASG News and Press, Passage Bio Inc. From 11/09/23

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Passage Bio Inc. (PASG) is expected to report $-0.47 for Q3 2023

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive office...

PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive offic...

2023-08-07 07:23:02 ET Passage Bio press release ( NASDAQ: PASG ): Q2 GAAP EPS of -$0.44 beats by $0.03 . Cash, cash equivalents and marketable securities were $151.5 million as of June 30, 2023, as compared to $239.3 million as of June 30, 2022. The Company expects cu...

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkers Dose 2 of PBGM01 was able to achieve healthy control levels of CSF �...

Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profile Dose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β - G al activ...

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of Dolan Sondhi, Ph.D., to the Board of Dire...

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive office...

2023-05-11 10:01:00 ET Passage Bio press release ( NASDAQ: PASG ): Q1 GAAP EPS of -$0.63 misses by $0.13 . Cash, cash equivalents and marketable securities were $167.8 million as of March 31, 2023, as compared to $267.1 million as of March 31, 2022. The Company expects...